

James Buchanan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5403704/publications.pdf>

Version: 2024-02-01

44
papers

1,849
citations

516215

16
h-index

288905

40
g-index

46
all docs

46
docs citations

46
times ranked

3063
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing women's preferences towards tests that may reveal uncertain results from prenatal genomic testing: Development of attributes for a discrete choice experiment, using a mixed-methods design. PLoS ONE, 2022, 17, e0261898.	1.1	4
2	Eliciting risk preferences that predict risky health behavior: A comparison of two approaches. Health Economics (United Kingdom), 2022, 31, 836-858.	0.8	10
3	Defining a Core Data Set for the Economic Evaluation of Precision Oncology. Value in Health, 2022, 25, 1371-1380.	0.1	6
4	Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. Applied Health Economics and Health Policy, 2022, 20, 501-524.	1.0	19
5	Factors that impact on women's decision-making around prenatal genomic tests: An international discrete choice survey. Prenatal Diagnosis, 2022, 42, 934-946.	1.1	5
6	Availability and funding of clinical genomic sequencing globally. BMJ Global Health, 2021, 6, e004415.	2.0	37
7	Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom. Applied Health Economics and Health Policy, 2021, 19, 521-535.	1.0	12
8	Toward the diagnosis of rare childhood genetic diseases: what do parents value most?. European Journal of Human Genetics, 2021, 29, 1491-1501.	1.4	22
9	Cost-Effectiveness of Amphotericin B Deoxycholate Versus Itraconazole for Induction Therapy of Talaromycosis in Human Immunodeficiency Virus-Infected Adults in Vietnam. Open Forum Infectious Diseases, 2021, 8, ofab357.	0.4	0
10	Public preferences for delayed or immediate antibiotic prescriptions in UK primary care: A choice experiment. PLoS Medicine, 2021, 18, e1003737.	3.9	3
11	What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK. Pharmacoeconomics, 2021, 39, 1443-1454.	1.7	4
12	100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care – Preliminary Report. New England Journal of Medicine, 2021, 385, 1868-1880.	13.9	352
13	The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom. Genetics in Medicine, 2020, 22, 85-94.	1.1	133
14	A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders. Pharmacoeconomics, 2020, 38, 143-158.	1.7	3
15	Delayed Antibiotic Prescription by General Practitioners in the UK: A Stated-Choice Study. Antibiotics, 2020, 9, 608.	1.5	4
16	Awareness of Appropriate Antibiotic Use in Primary Care for Influenza-Like Illness: Evidence of Improvement from UK Population-Based Surveys. Antibiotics, 2020, 9, 690.	1.5	3
17	Why do hospital prescribers continue antibiotics when it is safe to stop? Results of a choice experiment survey. BMC Medicine, 2020, 18, 196.	2.3	9
18	Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value in Health, 2020, 23, 566-573.	0.1	32

#	ARTICLE	IF	CITATIONS
19	Implications of secondary findings for clinical contexts. , 2020, , 155-201.		2
20	Do health professionals value genomic testing? A discrete choice experiment in inherited cardiovascular disease. <i>European Journal of Human Genetics</i> , 2019, 27, 1639-1648.	1.4	11
21	Duration of Treatment Effect Should Be Considered in the Design and Interpretation of Clinical Trials: Results of a Discrete Choice Experiment. <i>Medical Decision Making</i> , 2019, 39, 461-473.	1.2	9
22	The challenge of antimicrobial resistance: What economics can contribute. <i>Science</i> , 2019, 364, .	6.0	292
23	A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 443-452.	1.0	20
24	Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK. <i>PharmacoEconomics - Open</i> , 2019, 3, 281-291.	0.9	15
25	Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research. <i>PharmacoEconomics - Open</i> , 2019, 3, 129-132.	0.9	9
26	Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. <i>Genetics in Medicine</i> , 2018, 20, 1122-1130.	1.1	387
27	Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. <i>Value in Health</i> , 2018, 21, 1043-1047.	0.1	48
28	The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study. <i>Pharmacoeconomics</i> , 2018, 36, 1263-1272.	1.7	14
29	Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. <i>Value in Health</i> , 2018, 21, 1033-1042.	0.1	52
30	Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions. <i>Value in Health</i> , 2018, 21, 1048-1053.	0.1	17
31	Urgent improvements needed to diagnose and manage Lynch syndrome. <i>BMJ: British Medical Journal</i> , 2017, 356, j1388.	2.4	20
32	Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1088-1099.e5.	0.5	12
33	Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 845-858.	1.7	10
34	Health Economic Perspectives of Genomics. , 2016, , 83-117.		0
35	Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment. <i>Patient</i> , 2016, 9, 525-536.	1.1	29
36	Women's birth place preferences in the United Kingdom: a systematic review and narrative synthesis of the quantitative literature. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 213.	0.9	34

#	ARTICLE	IF	CITATIONS
37	Evidence used in model-based economic evaluations for evaluating pharmacogenetic and pharmacogenomic tests: a systematic review protocol. <i>BMJ Open</i> , 2015, 5, e008465-e008465.	0.8	4
38	Welfarism Versus Extra-Welfarism: Can the Choice of Economic Evaluation Approach Impact on the Adoption Decisions Recommended by Economic Evaluation Studies?. <i>Pharmacoeconomics</i> , 2015, 33, 571-579.	1.7	13
39	Can rapid integrated polymerase chain reaction-based diagnostics for gastrointestinal pathogens improve routine hospital infection control practice? A diagnostic study. <i>Health Technology Assessment</i> , 2014, 18, 1-167.	1.3	19
40	Issues surrounding the health economic evaluation of genomic technologies. <i>Pharmacogenomics</i> , 2013, 14, 1833-1847.	0.6	96
41	Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 301-316.	0.6	33
42	Cost-Effectiveness of Pre-Referral Antimalarial, Antibacterial, and Combined Rectal Formulations for Severe Febrile Illness. <i>PLoS ONE</i> , 2010, 5, e14446.	1.1	7
43	Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. <i>Genomic Medicine</i> , 2007, 1, 35-45.	0.6	34
44	Mixed-methods evaluation of the NHS Genomic Medicine Service for paediatric rare diseases: study protocol. <i>NIHR Open Research</i> , 0, 1, 23.	0.0	1